Neurocrine Biosciences, Inc. announced the publication of a post-hoc analysis in The Journal of Clinical Psychiatry, demonstrating the long-term safety profile and robust efficacy of INGREZZA capsules in adults aged 65 years and older with tardive dyskinesia (TD). This analysis was derived from two 48-week studies, the KINECT 3 extension and KINECT 4.
This represents the first and only published peer-reviewed analysis of a vesicular monoamine transporter 2 inhibitor for the treatment of TD in older adults, a population at higher risk for TD and associated consequences. The data showed substantial and sustained improvements in TD symptoms in older adults, with no new treatment-emergent adverse events of clinical concern compared with younger adults.
Participants 65 years and older achieved clinically meaningful improvements in TD symptoms within eight weeks of INGREZZA treatment, with sustained improvement up to 48 weeks. This adds to the breadth of evidence suggesting INGREZZA is suitable for this patient population, maintaining psychiatric stability throughout the treatment period.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.